Canopy Growth Corporation (CGC) Fair Value 2026

CGC · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (50/100)

Quick Summary — As of 2026-08-28, Canopy Growth Corporation (CGC) trades at $1.00. QOC: 5.3/10. Value Trap Risk: 50/100 (WARN). 1/13 models active.

Key Facts

Ticker
CGC
Price
$1.00
Quality Score
5.3/10
Value Trap Risk
50/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +93.5% upside with 34% confidence
Risk: Value Trap score of 50 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give CGC?

1 Intrinsic Value Models vs. Current Price ($1.00)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.93 +93.5%

All Models Active

All 1 models are displayed above.

What Is Canopy Growth Corporation (CGC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Canopy Growth Corporation's intrinsic value is estimated at a median fair value of $1.93. At a current market price of $1.00, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +93.5%.

What Do the Models Say About CGC?

1 of 13 models are currently active for CGC. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does CGC Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, CGC ranks #72 by Quality of Company score. CirclFi's QOC score of 5.3/10 evaluates 32 fundamental signals. A score of 5.3 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

Within the Drug Manufacturers - Specialty & Generic space, Canopy Growth Corporation competes in an environment where clinical trial success rate often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is CGC a Value Trap?

CirclFi's Value Trap algorithm assigns CGC a score of 50/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Canopy Growth Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Canopy Growth Corporation's fundamental quality profile registers 5.3/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CGC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CGC's 1 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Canopy Growth Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

YCBDcbdMD, Inc.QOC 5.3INMInMed Pharmaceuticals Inc.QOC 5.2CVSICV Sciences, Inc.QOC 5.4SKYISky Century Investment, Inc.QOC 5.2BFRIBiofrontera Inc.QOC 5.4IMCCIM Cannabis Corp.QOC 5.2RDHLRedHill Biopharma Ltd.QOC 4.1PBHPrestige Consumer Healthcare Inc.QOC 8.3CPIXCumberland Pharmaceuticals Inc.QOC 6.3UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: YCBD · INM · CVSI · SKYI · BFRI · IMCC · RDHL · PBH · CPIX · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to CGC?

7 companies across all industries closest to CGC’s Quality of Company score of 5.3/10.

AAQLAntiaging Quantum Living Inc.QOC 5.3CHKRChesapeake Granite Wash TrustQOC 5.3OCLNOriginClear, Inc.QOC 5.3BCHGGrayscale Bitcoin Cash TrustQOC 5.3BTBTBit Digital, Inc.QOC 5.3AMCAMC Entertainment Holdings, Inc.QOC 5.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AAQL · CHKR · OCLN · BCHG · BTBT · AMC · NVDA

Where Does CGC Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

CGC is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Canopy Growth Corporation’s Valuation?

What is Canopy Growth Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Canopy Growth Corporation (CGC). The Quality of Company score is 5.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CGC overvalued or undervalued right now?

At $1.00, 1 of 1 active models suggest CGC may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Canopy Growth Corporation's business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.3 mean for CGC?

Canopy Growth Corporation's QOC of 5.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CGC?

CirclFi analyzes CGC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CGC a value trap in 2026?

Canopy Growth Corporation's Value Trap score is 50/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Canopy Growth Corporation (CGC) a Quality of Company score of 5.3/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CGC/ · Methodology
Primary sources for this CGC valuation
  • Financial statements: Canopy Growth Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001737927) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CGC as of ; valuations recomputed .